News

The sponsor approved the participation of our center in a clinical trial of a new anticoagulant for the treatment of atrial fibrillation

A set of healthy volunteers aged 18-45 years has been opened to participate in the study of a new anti-tuberculosis vaccine for adults. Details of participation can be discussed with the chief researcher Professor Maria Vershinina - 89932027840 (WhatsApp)

A study begins to assess the tolerability, safety, and immunogenicity of a new influenza inactivated vaccine in children from 6 months to 17 years

Permission was obtained to conduct a study of the safety and effectiveness of a tuberculosis recombinant vaccine in relation to preventing the development of primary lung tuberculosis